GMT strategy is to pursue excellence and innovation at all levels, from manufacturing production units to quality systems and customer care.

GMT’s strategy is to supply a wide variety of therapeutically active substances used in the manufacture of pharmaceutical drug products, primarily used in oncology and women health.

The company has been successfully inspected by Swissmedic in 2024, the FDA in 2016 and has an Accreditation of Foreign Manufacturer from the Japanese PMDA since 2005.